FDA Approves New Treatment for Rare Airway Disease The U.S. Food and Drug Administration has granted accelerated approval to Inovio Pharmaceuticals’ Voceryq for recurrent respiratory papillomatosis, a rare condition that causes recurring growths in the throat and airways and can affect breathing and speech. People living with the condition often undergo repeated surgeries. Voceryq offers another potential treatment option, but accelerated approval requires a further study to confirm clinical benefit. It is not an established cure. The decision highlights a difficult balance: providing earlier access to promising therapies for people with limited options while continuing to demand reliable evidence about long-term outcomes. Discussion: Should regulators accelerate access to promising treatments for rare diseases before long-term evidence is complete? 😇